explore -WSS

explore

author：fashion 2025-10-01 21:48:13 - browse：38829

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： New lesbian bars spark hope amid disappearing LGBTQ+ spaces

WSS

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Can medical device makers keep up in the race to treat obesity?

Tuskegee Airman Raymond Cassagnol dies at 102

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Inside the rise of 'mukbang' eating videos

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

entertainment

explore

focus

23andMe had bad news about my health. I wish a person had delivered it

Living organ donors deserve priority status for transplants

Malaria cases in Florida and Texas: Here’s what you need to know

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Walensky prepares to leave CDC — and Congress — behind

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

United colonoscopy coverage change 'may cost lives,' doctors say

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Guidelines to prevent youth baseball injuries need more muscle

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

entertainment

GOP inquiry over gain

Eating disorder hotline's move to chatbot carried cost for volunteers

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Brazil's Jair Bolsonaro is barred from running for office until 2030

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Bispecific antibodies are next new thing in cancer immunotherapy

focus

leisure time

focus

knowledge